Gyre Therapeutics (GYRE) Assets Average (2011 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Assets Average of $164.1 million for Q1 2026, up 28.59% year-over-year from $127.6 million in Q1 2025, and up 0.81% quarter-over-quarter from $162.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Assets Average (2011 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Assets Average for 16 consecutive years, with $164.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 28.59% year-over-year to $164.1 million; the TTM figure through Mar 2026 stood at $164.1 million (up 28.59% YoY), while the FY2025 annual figure was $145.8 million, up 20.5% from the prior year.
- Assets Average advanced to $164.1 million in Q1 2026 per GYRE's latest filing, from $162.8 million in the prior quarter.
- Across five years, Assets Average topped out at $164.1 million in Q1 2026 and bottomed at $11.2 million in Q3 2023.
- Historically, Assets Average has averaged $94.6 million across 5 years, with a median of $119.3 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average plunged 80.45% — and 2024, when it soared 1001.03%.
- Gyre Therapeutics' Assets Average stood at $57.9 million in 2022, then advanced by 9.27% to $63.3 million in 2023, then jumped by 98.13% to $125.3 million in 2024, then gained by 29.87% to $162.8 million in 2025, then advanced by 0.81% to $164.1 million in 2026.
- Business Quant data shows GYRE's Assets Average at $164.1 million in Q1 2026, $162.8 million in Q4 2025, and $156.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 180.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 180.64 Mn |
| Mar 31, 2026 | 164.07 Mn |
| Dec 31, 2025 | 162.76 Mn |
| Sep 30, 2025 | 156.02 Mn |
| Jun 30, 2025 | 141.22 Mn |
| Mar 31, 2025 | 127.60 Mn |
| Dec 31, 2024 | 125.32 Mn |
| Sep 30, 2024 | 123.08 Mn |
| Jun 30, 2024 | 121.47 Mn |
| Mar 31, 2024 | 119.27 Mn |
| Dec 31, 2023 | 63.25 Mn |
| Sep 30, 2023 | 11.18 Mn |
| Jun 30, 2023 | 15.57 Mn |
| Mar 31, 2023 | 51.75 Mn |
| Dec 31, 2022 | 57.89 Mn |
| Sep 30, 2022 | 57.20 Mn |
| Jun 30, 2022 | 61.82 Mn |
| Mar 31, 2022 | 47.97 Mn |
| Dec 31, 2021 | 67.10 Mn |
| Sep 30, 2021 | 90.16 Mn |